Join Ross Camidge, MD, PhD, Brian Kavanagh, MD, MPH, and Michael Weyant, MD, as they present their multidisciplinary expertise on a range of cases pertaining to Locally Advanced NSCL Cancer: Stage IIIA Managment.
Most patients (85%) with lung cancer are diagnosed with non-small cell lung cancer (NSCLC). This tumor board will discuss stage IIIA NSCLC, because this is an area with the greatest controversy about treatment. Oncologists need to know the nuances of how to select the best treatment for stage IIIA NSCLC, which can be efficiently shown in an interesting tumor board scenario. The NCCN Guidelines recommend a multidisciplinary approach for patients with NSCLC to ensure the best possible treatment. It is essential to accurately determine the stage of disease before treatment. Unless patients have obvious metastatic disease, thorough pretreatment staging using imaging (e.g., CTs of the chest and upper abdomen, brain MRI, PET/CT scans) and pathologic mediastinal lymph node evaluation is recommended for most patients so that an accurate clinical stage can be used to guide preliminary treatment planning. Locally advanced NSCLC is stage III using the AJCC staging. Patients with stage III NSCLC have heterogenous disease with different amounts of lymph node involvement; thus, recommended treatment varies depending on the extent of disease. Because imaging studies are associated with false-positive nodes, pathologic confirmation of nodal disease is essential to avoid overtreatment. To confirm mediastinal lymph node status, minimally invasive techniques are now available such as EBUS, EUS, mediastinoscopy, and VATS.
Surgery may be recommended for patients with stage III disease followed by adjuvant treatment. Most surgeons agree that patients with preoperative stage IIIA disease may be candidates for surgery if they have a single N2 lymph node less than 3 cm. However, decision-making is more complicated for patients with multiple N2 nodes. Some patients presumed to have N1 disease before surgery may be found to have N2 disease during thoracotomy and therefore treatment planning may change based on surgical and pathologic results. After surgery, adjuvant treatment using either sequential or concurrent chemoradiation is recommended in the NCCN Guidelines. The type of adjuvant treatment depends on several factors, including whether the surgical margins are positive or negative; whether the resection was R0, R1, or R2; comorbidities; performance status; and patient preferences.
Advances in minimally invasive surgical techniques, imaging, and use of multimodality treatment are transforming the management of locally advanced NSCLC. Recent advances permit the rational development of treatment plans and use of multimodality therapy based on the amount of lymph node disease. Patient and physician discussions should include the importance of careful staging before deciding on a treatment plan. Patients should be aware that surgery may not be appropriate based on the results of testing and that treatment plans may need to be revised based on testing.
NCCN is offering a series of twelve multidisciplinary case-based webinars on a variety of topics, including Lymphoma: Mantle Cell, Lymphoma: CLL/SLL, Chronic Phase CML, Multiple Myeloma, Breast Cancer: Adjuvant Systemic Therapy, Breast Cancer: Advanced Disease, Lung Cancer: Biomarker Driven Advanced Disease, Lung Cancer: Locally Advanced NSCLC: Stage IIIA Management, Metastatic Colorectal Cancer, Prostate Cancer: Castrate Resistant, Melanoma, and Kidney Cancer. Each webinar will be facilitated by two faculty members providing multidisciplinary perspectives. A different topic will be presented each month for twelve months (June 2014 until June 2015).
The NCCN Guidelines are a set of step-by step evidence-based, consensus-driven recommendations that ensure that patients receive preventive, diagnostic treatment, and care that is most likely to lead to optimal outcomes. The NCCN recommendations are applicable to about 95% of patients. Clinicians need to consider the current clinical status of the patient, including general health, disease specifics, concomitant conditions, current and previous therapies, and the patients how to best apply appropriate standard of care including identifying circumstances where appropriate management requires adapting the NCCN Guidelines to the needs of the individual. This activity series will discuss the specific recommendations in the NCCN Guidelines as well as unique patient circumstances that impact how the NCCN Guidelines might be best applied.
Thursday, August 7, 2014 5:00 PM - 6:00 PMEastern Time
NCCN Meetings Department
World Time Zone MapSee when meeting occurs in other time zonesWorld Time Zone Map
NCCN.org – For Clinicians | NCCN.org/patients – For Patients
National Comprehensive Cancer Network | 275 Commerce Drive | Suite 300 | Fort Washington | PA | 19034 | US | 215.690.0300